CXCL12/CXCR4 Axis in the Pathogenesis of Acute Lymphoblastic Leukemia (ALL): a Possible Therapeutic Target

Overview

Journal Cell Mol Life Sci

Publisher Springer

Specialty Biology

Date 2015 Jan 10

PMID 25572297

Citations 23

Authors

Aparecida de Lourdes Perim

Marla Karine Amarante

Roberta Losi Guembarovski

Carlos Eduardo Coral de Oliveira

Maria Angelica Ehara Watanabe

Affiliations

Soon will be listed here.

Abstract

Acute lymphoblastic leukemia (ALL) is the commonest childhood malignancy, accounting for approximately 80 % of leukemia in the pediatric group, and its etiology is unknown. This neoplasia is characterized by male predominance, high-risk features and poor outcome, mainly in recurrence patients and adults. In recent years, advances in the success of childhood ALL treatment were verified, and the rate of cure is over 80 % of individuals. However, there is a considerable scope for improving therapeutic outcome in this neoplasia. Improvements in ALL therapy might readily be achieved by developing additional biomarkers that can predict and refine prognosis in patients with ALL. In normal hematopoietic cells, cytokines provide the stimulus for proliferation, survival, self-renewal, differentiation and functional activation. Abnormalities of cytokines are characteristic in all forms of leukemia, including ALL. The stromal cell-derived factor-1 (SDF-1 or CXCL12) is a member of the CXC chemokine family that binds to CXC chemokine receptor 4 (CXCR4). The CXCL12/CXCR4 axis appears to play a role in dissemination of solid tumors and hematopoietic diseases. Understanding the mechanisms by which ALL cells are disseminated will provide additional information to expand therapeutic approach. Therefore, this review summarizes information relating to ALL cell biology, focusing specifically in a cytokine receptor important axis, CXCL12/CXCR4, that may have implications for novel treatment strategies to improve life expectancy of patients with this neoplasia.

Citing Articles

The role of chemokines and interleukins in acute lymphoblastic leukemia: a systematic review.

Stajer M, Horacek J, Kupsa T, Zak P J Appl Biomed. 2025; 22(4):165-184.

PMID: 40033805 DOI: 10.32725/jab.2024.024.

Pediatric T-cell acute lymphoblastic leukemia blast signature and MRD associated immune environment changes defined by single cell transcriptomics analysis.

Bhasin S, Thomas B, Summers R, Sarkar D, Mumme H, Pilcher W Sci Rep. 2023; 13(1):12556.

PMID: 37532715 PMC: 10397284. DOI: 10.1038/s41598-023-39152-z.

The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives.

Caracciolo D, Mancuso A, Polera N, Froio C, DAquino G, Riillo C Exp Hematol Oncol. 2023; 12(1):5.

PMID: 36624522 PMC: 9828428. DOI: 10.1186/s40164-022-00368-w.

Leukemia's Next Top Model? Syngeneic Models to Advance Adoptive Cellular Therapy.

Zoine J, Moore S, Velasquez M Front Immunol. 2022; 13:867103.

PMID: 35401520 PMC: 8990900. DOI: 10.3389/fimmu.2022.867103.

Fast H3K9 methylation promoted by CXCL12 contributes to nuclear changes and invasiveness of T-acute lymphoblastic leukemia cells.

Madrazo E, Gonzalez-Novo R, Ortiz-Placin C, Garcia de Lacoba M, Gonzalez-Murillo A, Ramirez M Oncogene. 2022; 41(9):1324-1336.

PMID: 34999734 DOI: 10.1038/s41388-021-02168-8.

References

de Lourdes Perim A, Guembarovski R, Oda J, Lopes L, Ariza C, Amarante M . CXCL12 and TP53 genetic polymorphisms as markers of susceptibility in a Brazilian children population with acute lymphoblastic leukemia (ALL). Mol Biol Rep. 2013; 40(7):4591-6. DOI: 10.1007/s11033-013-2551-1. View

Busillo J, Benovic J . Regulation of CXCR4 signaling. Biochim Biophys Acta. 2006; 1768(4):952-63. PMC: 1952230. DOI: 10.1016/j.bbamem.2006.11.002. View

Van Vlierberghe P, Ferrando A . The molecular basis of T cell acute lymphoblastic leukemia. J Clin Invest. 2012; 122(10):3398-406. PMC: 3461904. DOI: 10.1172/JCI61269. View

Bartram C, Schrauder A, Kohler R, Schrappe M . Acute lymphoblastic leukemia in children: treatment planning via minimal residual disease assessment. Dtsch Arztebl Int. 2012; 109(40):652-8. PMC: 3476612. DOI: 10.3238/arztebl.2012.0652. View

Harrison C . Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia. Br J Haematol. 2008; 144(2):147-56. DOI: 10.1111/j.1365-2141.2008.07417.x. View

Mullighan C . Molecular genetics of B-precursor acute lymphoblastic leukemia. J Clin Invest. 2012; 122(10):3407-15. PMC: 3461902. DOI: 10.1172/JCI61203. View

Silverman L, Gelber R, Dalton V, Asselin B, Barr R, Clavell L . Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001; 97(5):1211-8. DOI: 10.1182/blood.v97.5.1211. View

Welschinger R, Liedtke F, Basnett J, Dela Pena A, Juarez J, Bradstock K . Plerixafor (AMD3100) induces prolonged mobilization of acute lymphoblastic leukemia cells and increases the proportion of cycling cells in the blood in mice. Exp Hematol. 2012; 41(3):293-302.e1. DOI: 10.1016/j.exphem.2012.11.004. View

Janowski M . Functional diversity of SDF-1 splicing variants. Cell Adh Migr. 2009; 3(3):243-9. PMC: 2712802. DOI: 10.4161/cam.3.3.8260. View

10.

Hosking F, Papaemmanuil E, Sheridan E, Kinsey S, Lightfoot T, Roman E . Genome-wide homozygosity signatures and childhood acute lymphoblastic leukemia risk. Blood. 2010; 115(22):4472-7. DOI: 10.1182/blood-2009-09-244483. View

11.

Bradstock K, Makrynikola V, Bianchi A, Shen W, Hewson J, Gottlieb D . Effects of the chemokine stromal cell-derived factor-1 on the migration and localization of precursor-B acute lymphoblastic leukemia cells within bone marrow stromal layers. Leukemia. 2000; 14(5):882-8. DOI: 10.1038/sj.leu.2401729. View

12.

Schneider P, Vasse M, Al Bayati A, Lenormand B, Vannier J . Is high expression of the chemokine receptor CXCR-4 of predictive value for early relapse in childhood acute lymphoblastic leukaemia?. Br J Haematol. 2002; 119(2):579-80. DOI: 10.1046/j.1365-2141.2002.03835_6.x. View

13.

Parameswaran R, Yu M, Lim M, Groffen J, Heisterkamp N . Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist. Leukemia. 2011; 25(8):1314-23. PMC: 3135709. DOI: 10.1038/leu.2011.76. View

14.

Kucia M, Jankowski K, Reca R, Wysoczynski M, Bandura L, Allendorf D . CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J Mol Histol. 2004; 35(3):233-45. DOI: 10.1023/b:hijo.0000032355.66152.b8. View

15.

Ganju R, Brubaker S, Meyer J, Dutt P, Yang Y, Qin S . The alpha-chemokine, stromal cell-derived factor-1alpha, binds to the transmembrane G-protein-coupled CXCR-4 receptor and activates multiple signal transduction pathways. J Biol Chem. 1998; 273(36):23169-75. DOI: 10.1074/jbc.273.36.23169. View

16.

Tavor S, Petit I . Can inhibition of the SDF-1/CXCR4 axis eradicate acute leukemia?. Semin Cancer Biol. 2010; 20(3):178-85. DOI: 10.1016/j.semcancer.2010.07.001. View

17.

de Oliveira K, Oda J, Voltarelli J, Nasser T, Ono M, Fujita T . CXCL12 rs1801157 polymorphism in patients with breast cancer, Hodgkin's lymphoma, and non-Hodgkin's lymphoma. J Clin Lab Anal. 2009; 23(6):387-93. PMC: 6649101. DOI: 10.1002/jcla.20346. View

18.

Crazzolara R, Kreczy A, Mann G, Heitger A, Eibl G, Fink F . High expression of the chemokine receptor CXCR4 predicts extramedullary organ infiltration in childhood acute lymphoblastic leukaemia. Br J Haematol. 2001; 115(3):545-53. DOI: 10.1046/j.1365-2141.2001.03164.x. View

19.

Tzeng Y, Li H, Kang Y, Chen W, Cheng W, Lai D . Loss of Cxcl12/Sdf-1 in adult mice decreases the quiescent state of hematopoietic stem/progenitor cells and alters the pattern of hematopoietic regeneration after myelosuppression. Blood. 2010; 117(2):429-39. DOI: 10.1182/blood-2010-01-266833. View

20.

Tokoyoda K, Egawa T, Sugiyama T, Choi B, Nagasawa T . Cellular niches controlling B lymphocyte behavior within bone marrow during development. Immunity. 2004; 20(6):707-18. DOI: 10.1016/j.immuni.2004.05.001. View